Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimal treatment of drug resistant hypertension

Trial Profile

Optimal treatment of drug resistant hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxazosin (Primary) ; Bisoprolol; Spironolactone
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms PATHWAY-2

Most Recent Events

  • 16 Feb 2016 Results published in the Annals of Internal Medicine
  • 26 Jul 2015 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
  • 15 Nov 2014 Planned End Date changed from 30 Jun 2015 to 21 Jul 2014 according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top